|
市場調査レポート
商品コード
1446176
神経バイオマーカーの世界市場 2024-2028Global Neurological Biomarkers Market 2024-2028 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。 |
神経バイオマーカーの世界市場 2024-2028 |
出版日: 2024年02月27日
発行: TechNavio
ページ情報: 英文 175 Pages
納期: 即納可能
|
神経バイオマーカー市場は2023-2028年に78億2,000万米ドル、予測期間中のCAGRは13.01%で成長すると予測されています。
当レポートでは、神経バイオマーカー市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。
現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。神経疾患の罹患率の上昇、神経疾患特異的バイオマーカーの臨床試験の増加、神経ヘルスケアへのアクセスを改善するための政府による取り組みや支援の増加が市場を牽引しています。
市場範囲 | |
---|---|
基準年 | 2024 |
終了年 | 2028 |
予測期間 | 2024-2028 |
成長モメンタム | 加速 |
前年比2024年 | 12.2% |
CAGR | 13.01% |
増分額 | 78億2,000万米ドル |
本調査では、今後数年間の神経バイオマーカー市場成長を牽引する主な要因の一つとして、正確な神経学的診断への注目の高まりを挙げています。また、血液ベースのバイオマーカーの利用可能性の高まりとマニュアルmiRNAの進化は、市場の大きな需要につながります。
Exhibits:
The neurological biomarkers market is forecasted to grow by USD 7.82 bn during 2023-2028, accelerating at a CAGR of 13.01% during the forecast period. The report on the neurological biomarkers market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising incidence of neurological disorders, growth in clinical trials for neurological disease-specific biomarkers, and increasing initiatives and support from governments to improve neurological healthcare access.
Technavio's neurological biomarkers market is segmented as below:
Market Scope | |
---|---|
Base Year | 2024 |
End Year | 2028 |
Series Year | 2024-2028 |
Growth Momentum | Accelerate |
YOY 2024 | 12.2% |
CAGR | 13.01% |
Incremental Value | $7.82bn |
By End-user
By Indication
By Geographical Landscape
This study identifies the increasing focus on accurate neurological diagnostics as one of the prime reasons driving the neurological biomarkers market growth during the next few years. Also, growing availability of blood-based biomarkers and evolution of manual miRNA will lead to sizable demand in the market.
The report on the neurological biomarkers market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neurological biomarkers market vendors that include Abbott Laboratories, ACROBIOSYSTEMS INC., Advanced Brain Monitoring Inc., Alseres Pharmaceuticals Inc, Bio Rad Laboratories Inc., bioMerieux SA, Charles River Laboratories International Inc., EATRIS ERIC, Eli Lilly and Co., Enzo Biochem Inc., F. Hoffmann La Roche Ltd., Fujirebio Holdings Inc., IQVIA Holdings Inc., Merck KGaA, Metabolon Inc., PerkinElmer Inc, Proteome Sciences plc, QIAGEN NV, Quanterix Corp., and Thermo Fisher Scientific Inc.. Also, the neurological biomarkers market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.